Intravenous Iron Sucrose
Treatment for Iron Deficiency Anemia
Typical Dosage: Cumulative 1000 mg over several infusions
Effectiveness
88%
Safety Score
68%
Clinical Trials
46
Participants
20K
Comparative Safety Scale(Higher is safer)
Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
68
DangerousModerateSafe
Treatment Details
Dosage Range
Cumulative 1000 mg over several infusions
Time to Effect
2-4 weeks
Treatment Duration
2 weeks initially, then as needed
Evidence Quality
HIGHNumber Needed to Treat (NNT)
5(Treat 5 patients to see 1 additional successful outcome)
Number Needed to Harm (NNH)
150(Treat 150 patients to see 1 additional serious adverse event)
Confidence Score
90%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$800
Monitoring:$2,100
Side Effect Mgmt:$100
Total Annual:$3,000
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
GOODICER
$55,000/QALY
QALYs Gained
0.3
Outcome-Based Costs
Cost per Responder
$3,529
Cost per Remission
$3,871
Comparison vs Oral Ferrous Sulfate
Cost Difference
+$2,530/year
More expensive
QALY Difference
+0.10 QALYs
Better outcomes
Dominance
No dominance
Prescription Access Economics
Risk Assessment
Requires Monitoring
YesNeeds lab work/checkups
Intravenous Iron Sucrose Outcomes
for Iron Deficiency Anemia
Efficacy Outcomes
Overall Effectiveness
+88%
Response Rate
+85%
Remission Rate
+77.5%
Common Side Effects
Hypotension (transient)
+2%
Nausea
+2%
Headache
+1%
Injection site reactions
+1%
Muscle cramps
+1%
Hypersensitivity/Anaphylaxis
+0.1%
Active Clinical Trials
2 active trials recruiting for Intravenous Iron Sucrose in Iron Deficiency Anemia
Ferric Derisomaltose (Iron Isomaltoside) Versus Iron Sucrose for Treatment of Iron Deficiency in Pregnancy
NCT05251493RECRUITINGPHASE3
280 participants
INTERVENTIONAL
Regina, Canada
Started: Jun 6, 2022
Intravenous Iron Versus Oral Iron for the Treatment of Iron Deficiency Anemia
NCT06366698RECRUITINGPHASE3
900 participants
INTERVENTIONAL
Colton, United States
Started: Nov 21, 2023
Completed Clinical Trials
9 completed trials for Intravenous Iron Sucrose in Iron Deficiency Anemia
Iron Isomaltoside/Ferric Derisomaltose vs Iron Sucrose for the Treatment of Iron Deficiency Anemia (IDA)
NCT02940886COMPLETEDPHASE3
1.51K participants
INTERVENTIONAL
Birmingham, United States +113 more
Started: Nov 8, 2016
IDA-01 A Randomised, Open-Label, Comparative Study of Intravenous Iron Isomaltoside 1000 (Monofer®) and Iron Sucrose
NCT02130063COMPLETEDPHASE3
511 participants
INTERVENTIONAL
Wilmington, United States
Started: May 1, 2014
Efficacy Study of Intravenous Iron Preparation to Iron Deficiency Anemia
NCT02731534COMPLETEDPHASE3
238 participants
INTERVENTIONAL
Tokyo, Japan
Started: May 1, 2016
Ferric Carboxymaltose Versus Iron Sucrose for Treating Anemia in Pregnant Women
NCT06911034COMPLETEDPHASE4
60 participants
INTERVENTIONAL
Multan, Pakistan
Started: Feb 1, 2024
Intravenous Ferric Carboxymaltose vs IV Iron Sucrose or IV Iron Dextran in Treating Iron Deficiency Anemia in Women
NCT01290315COMPLETEDPHASE2
49 participants
INTERVENTIONAL
Norristown, United States
Started: Aug 1, 2009
Iron Supplementation for Acute Anemia After Postbariatric Abdominoplasty
NCT01857011COMPLETEDPHASE3
56 participants
INTERVENTIONAL
São Paulo, Brazil
Started: Apr 1, 2014
Iron Isomaltoside/Ferric Derisomaltose vs Iron Sucrose for Treatment of Iron Deficiency Anemia in Non-Dialysis-Dependent Chronic Kidney Disease
NCT02940860COMPLETEDPHASE3
1.54K participants
INTERVENTIONAL
Huntsville, United States +140 more
Started: Nov 29, 2016
Efficacy and Safety Study of Iron Sucrose and Oral Iron Acetyl-transferrin Hydroglycerin
NCT00802139COMPLETEDPHASE4
58 participants
INTERVENTIONAL
Kwangju, South Korea +2 more
Started: Feb 1, 2008
Iron Sucrose Versus Ferrous Bis-glycinate for Treatment of Iron Deficiency Anemia
NCT03009578COMPLETEDPHASE3
100 participants
INTERVENTIONAL
Asyut, Egypt
Started: Feb 1, 2017
Showing 20 of 46 total trials